<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">Dyslipidemia</z:e> is a prominent feature of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> that contributes to increased <z:hpo ids='HP_0002621'>atherosclerosis</z:hpo> and <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e>) risks under these conditions </plain></SENT>
<SENT sid="1" pm="."><plain>Incretin-based therapies (GLP-1 receptor <z:chebi fb="4" ids="48705">agonists</z:chebi> and DPP-4 inhibitors) have recently been developed and are approved for clinical use for treatment of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>Besides improved glycemic control, other benefits are being increasingly appreciated, one of which is improved plasma <z:chebi fb="23" ids="18059">lipid</z:chebi> profile </plain></SENT>
<SENT sid="3" pm="."><plain>This review aims to summarize the evidence and potential mechanism of such agents in humans in modulating fasting and postprandial <z:chebi fb="1" ids="6495">lipoprotein</z:chebi> metabolism </plain></SENT>
</text></document>